2022 Top 15 best-selling cancer drugs.(I)

.

If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma’s top 15 list of cancerdrugs in 2022 should eliminate it. 

All told, by 2022, the top 15 cancer drugs are expected to collectively make almost $90 billion in sales. 
To put that in perspective, that represents about one-fourth of the entire U.S. pharma market in 2014, according to QuintilesIMS data. 
It’s also bigger than pharma’s haul in Japan or China that year.(...)

Ver también:

Oncologia "al alza"...

To illustrate the fast pace of change in oncology, take a look at the big names that have disappeared since our last top cancer drug list just three years ago. Among the missing are Takeda’s multiple myeloma drug Velcade and Johnson & Johnson’s oral prostate cancer med Zytiga, both of which are expected to be superseded by newer drugs and could potentially face generics if patent suits don’t go their way. Others, notably Novartis’ Gleevec and Eli Lilly’s Alimta, will certainly see sales hit by generic rivals. 

Even as the immuno-oncology meds have ascended, nine of the top-selling 15 drugs in 2022 will still be monoclonal antibodies. First approved in the late 1990s, these therapies quicklybecame the preferred option for various cancers, and particularly blood cancer. Three of these— all from Roche—are first-generation cancer antibodies due to face biosimilar competition within the next couple of years. At the moment, it’s tough to predict just how much biosimilar copies will eat into their sales. But the fact that the three are predicted to remain in the top flight after decades on the market indicates that brand strength will still play a major role.

Ver:

Roche derrocha y...toma los "cielos (de la oncología) por asalto".

Ver: 
Todo sobre oncología en PHARMACOSERÍAS